Browse
···
Log in / Register

★$150 Video Game In-home Study!★ (Murray Hill)

$150/day

357A 8th Ave, New York, NY 10001, USA

Favourites
Share

Description

VGM is hosting an in-home study in New York City for video gamers ages 18+! You will have the unique opportunity to preview an unreleased video game, product, or feature and give your feedback to change the way the final version is made. Qualified participants will receive $150 for participation! Apply Here: -- CLICK HERE to apply! Held on Friday, October 24th or Saturday, October 25th In New York City For adults ages 18+ Participants will be required to come to our facility for up to 45 minutes to get set up. After setup, you will be asked to complete specific tasks at home during a month period for compensation. Participants will receive $150! Can't make it this time? Sign up for our invitation list, and we'll contact you whenever we schedule a new playtest in your area! Invitation List: http://www.vgm.co/signup See what our past participants have said and "like" us at our Facebook page! Facebook Page: http://www.facebook.com/vgmarket

Source:  craigslist View original post

Location
357A 8th Ave, New York, NY 10001, USA
Show map

craigslist

You may also like

Craigslist
Research Study for Adults with First Episode/Early Phase Schizophrenia (Chicago)
Hello, I wanted to let you know about a study that is taking place at our clinic. This study is sponsored by Vanguard Research Group and our clinic is one of the research sites helping them with this study. What is the purpose of this study? Schizophrenia is a condition that negatively affects people’s mental health in different ways. For example, it can affect a person’s mood, behavior, or cognition. Cobenfy is a new FDA approved drug for the treatment of the positive symptoms of schizophrenia. Cobenfy is different from other antipsychotics as it has a new “mechanism of action” compared to all other antipsychotics approved from the treatment of schizophrenia at this time. Since Cobenfy is the first medication of its drug class to be FDA approved for schizophrenia, researchers are interested to know how this new class of antipsychotics affects those with early phase schizophrenia specifically. This clinical trial will test if Cobenfy can help improve the positive symptoms of patients with first episode/early phase schizophrenia, better than other antipsychotics. To be eligible to participate, you must: ❖ Be at least 18 years or older ❖ Have a primary diagnosis of schizophrenia ❖ Have been on a stable dose of 1 antipsychotic medication for at least 8 weeks before treatment with no dose changes within the last 4 weeks. ❖ Have started your first antipsychotic treatment within the past 5 years. Patients who meet eligibility criteria and enroll will come into our office to receive the study drug. Once enrolled, in-person clinic visits will occur every 1-4 weeks for about 24 weeks until the end of treatment visit, with a final follow-up visit 28 days after you last take the study drug (no more than 13 visits total). If you decide to participate, the study drug will be provided by/paid for by our clinic and study related assessments will be conducted during clinic visits. You may also be compensated for your participation and be reimbursed for any study-related travel. Want to learn more? If you or someone you know is interested in learning more about this research study, please feel free to contact us by calling 312-503-9092 or emailing. Thank you for your time and I hope to hear from you soon. Principal Investigator: Jeffrey Rado, MD STU00223950
187 E Pearson St, Chicago, IL 60611, USA
$100-125/day
Craigslist
Paid Research Study for People Diagnosed with Depression (Chicago)
Do you struggle with symptoms of depression? You may be able to take part in a research study. Some people experience decreased motivation, trouble finding enjoyment in everyday activities, and difficulty with sleep because of their depression. These challenges—known as symptoms of depression—can significantly affect daily life and overall well-being. Unfortunately, the medications available don’t always fully relieve these symptoms. The OARS-7 Study is examining a new investigational medication added on to your current treatment to potentially provide additional support for individuals struggling with motivation and enjoyment and insomnia due to depression. What is the OARS-7 Study? The OARS-7 study is two parts. If you are eligible to take part in the study, you have the option to complete both parts. The first part is a randomized control trial of the study medication versus a placebo. The second part is an open label treatment phase for study medication and a second subsequent randomized control trial for study medication versus placebo. The results of this study could help other people who experience symptoms of depression and need additional support. Who can take part? You may qualify for the OARS-7 Study if you are: • Between the ages of 18-74 • Have a primary diagnosis of Major Depressive Disorder (MDD) • Have been on a stable dose of an antidepressant medication (SSRI/SNRI) • Are still experiencing symptoms of depression This research study is completely voluntary. If you qualify, you do not have to join the study, and if you do join, you can leave the study at any time. Interested? Contact us at: 312-503-7071 https://sites.northwestern.edu/mindtrials/research/current-trials-for-depression/ Principal Investigator: Jeffrey Rado, MD STU00223008
187 E Pearson St, Chicago, IL 60611, USA
$150/day
Cookie
Cookie Settings
Our Apps
Download
Download on the
APP Store
Download
Get it on
Google Play
© 2025 Servanan International Pte. Ltd.